Noteworthy clinical case studies in cancer gene therapy: Tumortargeted rexin-G advances as an efficacious anti-cancer agent

International Journal of Oncology

Volumn 36, Issue 6, 2010, Pages 1341-1353

  Gordon, Erlinda M ^a   Hall, Frederick L ^a  

^a Epeius Biotechnologies Corporation   (United States)

Author keywords

Cell cycle; Cyclin G1; Gene delivery; Metastatic cancer; Pathotropic targeting; Targeted genetic medicine; Tumor response criteria

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; FIGITUMUMAB; FLUOROURACIL; FULVESTRANT; GEMCITABINE; IFOSFAMIDE; INTERFERON; METHOTREXATE; MONOCLONAL ANTIBODY; PACLITAXEL; REXIMMUNE C; REXIN G; RG 1507; TAMOXIFEN; UNCLASSIFIED DRUG;

ABDOMINAL HYSTERECTOMY; ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AXILLARY LYMPH NODE; BILE DUCT BYPASS; BONE METASTASIS; BRAIN METASTASIS; BREAST CARCINOMA; CANCER GENE THERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CHOLECYSTECTOMY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EWING SARCOMA; HISTOPATHOLOGY; HUMAN; LIMB SALVAGE; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MASTECTOMY; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; SALPINGOOOPHORECTOMY; SIDE EFFECT; SPINE METASTASIS; THORACOTOMY; THORAX WALL; TREATMENT RESPONSE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CYCLIN G1; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; NANOPARTICLES; OSTEOSARCOMA; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; RETROVIRIDAE; SARCOMA, EWING'S;

EID: 77951608406     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000619     Document Type: Article

References (40)

1. Retrovector encoding mutant anti-cyclin G1 (Code C49082). NCI thesaurus http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp? dictionary= NCI%20Thesaurus&code=C49082
2. Gordon EM and Hall FL: Nanotechnology blooms, at last (Review). Oncol Rep 13: 1003-1007, 2005.
3. Gordon EM, Levy JP, Reed RA, Petchpud WN, Liu L, Wendler CB and Hall FL: Targeting metastatic cancer from the inside: A new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. Int J Oncol 33: 665-675, 2008.
4. Hall FL, Gordon EM, Wu L, Zhu NL, Skotzko MJ, Starnes VA and Anderson WF: Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMuLV gp70 envelope protein. Hum Gene Ther 8: 2183-2192, 1997. (Pubitemid 28043556)
5. Hall FL, Liu L, Zhu NL, Stapfer M, Anderson WF, Beart RW and Gordon EM: Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum Gene Ther 11: 983-993, 2000. (Pubitemid 30250115)
6. Gordon EM, Liu PX, Zhen SH, Liu L, Whitley MD, Gee C, Groshen S, Hinton DR, Beart RW and Hall FL: Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res 60: 3343-3347, 2000. (Pubitemid 30482143)
7. Gordon EM, Liu PX, Chen ZH, Liu L, Whitley MD, Liu L, Wei D, Groshen S, Hinton DR, Beart RW, Anderson WF and Hall FL: Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther 12: 193-204, 2001. (Pubitemid 32095457)
8. Wu L, Liu L, Yee A, Carbonaro-Hall D, Tolo V and Hall F: Molecular cloning of the human CYCG1 gene encoding a G-type cyclin: overexpression in osteosarcoma cells. Oncol Rep 1: 705-711, 1994. (Pubitemid 2099327)
9. Xu F, Prescott MF, Liu PX, Chen ZH, Liau G, Gordon EM and Hall FL: Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct. Int J Mol Med 8: 19-30, 2001.
10. Gordon EM, Chan MT, Geraldino N, Lopez FF, Cornelio GH, Lorenzo CC III, Levy JP, Reed RA, Liu L and Hall FL: Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. Int J Oncol 30: 1297-1307, 2007.
11. Gordon EM, Cornelio GH, Lorenzo CC, Levy JP, Reed RA, Liu L and Hall FL: First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for Stage IV pancreatic cancer. Int J Oncol 24: 177-185, 2004.
12. Gordon EM, Lopez FF, Cornelio GH, Lorenzo CC III, Levy JP, Reed RA, Liu L, Bruckner HW and Hall FL: Pathotropic nanoparticles for cancer gene therapy. Rexin-G™: three-year clinical experience. Int J Oncol 29: 1053-1064, 2006.
13. Galanis E, Carlson SK, Foster NR, Lowe V, Quevedo F, McWilliams RR, Grothey A, Jatoi A, Alberts SR and Rubin J: Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. Mol Ther 16: 979-984, 2008. (Pubitemid 351587110)
14. Chawla SP, Chua VS, Fernandez L, Quon D, Saralou A, Blackwelder WC, Hall FL and Gordon EM: Phase I/II and and Phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant osteosarcoma and other sarcomas. Mol Ther 17: 1651-1657, 2009.
15. Chawla SP, Chua VS, Fernandez L, Quon D, Blackwelder WC, Gordon EM and Hall FL: Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer. Mol Ther:doi:10.1038/ mt2009.228, 2009.
16. Gordon EM and Hall FL: The 'timely development' of Rexin-G: first targeted injectable gene vector (Review). Int J Oncol 35: 229-238, 2009.
17. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Giovannini C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L and Negrini M: Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67: 6092-6099, 2007. (Pubitemid 47037488)
18. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M and Bolondi L: MiR-122/cyclin G1 interaction modulates 53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 69: 5761-5767, 2009.
19. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P and Ghoshal K: MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 284: 32015-32027, 2009.
20. Coulouarn C, Factor VM, Andersen JB, Durkin ME and Thorgeirsson SS: Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526-3536, 2009.
21. Gordon EM and Hall FL: A primer on pathotropic medicine. In: Celebrating One Hundred Years of the Food and Drug Administration. A Special Centennial Edition. Brooklands New Media Ltd., Oswestry, Shropshire, UK, pp80-83, 2007.
22. Banks WA, Freed EO, Wolf KM, Robinson SM, Franko M and Kumar VB: Transport of human immunodeficiency virus Type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsorptive endocytosis. J Virol 75: 4681-4691, 2001. (Pubitemid 32381510)
23. Groothuis DR: The blood-brain and blood-tumor barriers: a review of strategies for increasing drug concentration. Neurooncology 2: 45-59, 2000.
24. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK and Tempero MA: Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 93: 195-199, 2005. (Pubitemid 41133205)
25. Wong D, Hwang J, Venook AP, Bergsland EK and Tempero MA: Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas 37: 269-274, 2008.
26. Hippocrates: The oath and law of Hipprocrates. The Harvard Classics, New York: P.F. Collier & Son, 1909-1914;
27. Bartleby. com, Vol.38: Part I, 2001. www.bartleby.com/38/1
28. Boeck S and Heinemann V: Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol 26: 1178-1179, 2008.
29. Nieto J, Grossbard ML and Kozuch P: Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 13: 562-576, 2008.
30. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE and Sarkar FH: Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69: 2400-2407, 2009
31. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ and Choi W: Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69: 5820-5828, 2009.
32. Almhanna K and Kim R: Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard? Oncology 22: 1176-1183, 2008.
33. Burris H III and Rocha-Lima C: New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 3: 289-298, 2008.
34. Cartwright T, Richards DA and Boehm KA: Cancer of the pancreas: are we making progress? a review of studies in the US Oncology Research Network. Cancer Control 15: 308-313, 2008.
35. Marshall JL: Vascular endothelial growth factor plus epidermal growth factor receptor dual targeted therapy in metastatic colorectal cancer: synergic or antagonism? J Oncol: 937305 Epub 2009 Dec 6, 2009.
36. Punt CJ and Tol J: More is less - combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol 6: 731-733, 2009.
37. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D and Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231, 2009.
38. Kerbel RS: Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast 18: S41-S47, 2009.
39. Wahl RL, Jacene H, Kasamon Y and Lodge MA: From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50 (Suppl. 1): S122-S150, 2009.
40. Roca-Lima CMSP and Flores AM: Gemcitabine doublets in advanced pancreatic cancer: should we move on? J Clin Oncol 24: 327-329, 2006.